Blueprint stumbles in PhIII GIST trial, sending stock sliding, but analysts preach caution
When the FDA approved Blueprint’s first drug three months ago, they split their decision. Ayvakit would be approved for gastrointestinal stromal tumors (GIST) with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
